MANKIND PHARMA LIMITED

Mankind Pharma Limited reported a 13% year-on-year increase in overall revenue for Q1 FY27, reaching INR 4,031 crores, with an EBITDA of INR 1,060 crores and an EBITDA margin improvement of 250 bps to 26.3%. The domestic business, excluding Consumer Healthcare, grew by 11% to INR 3,180 crores, driven by strong performance in chronic and specialty segments. The company noted a significant shift towards chronic therapies, with a 40% share in chronic business, aiming for 50% in the medium term. The Consumer Healthcare segment generated INR 246 crores, impacted by a discontinued cash and carry business but gained market share in key brands. The international business saw a 29% revenue growth to INR 605 crores. Management emphasized a focus on innovation and strategic partnerships to enhance R&D capabilities. The company aims for sustainable long-term growth while maintaining affordability in healthcare.

Management highlighted improvements in key financial metrics and growth across various business segments.